Clinical Study of BCL-2 Inhibitor Combined Therapy in the Treatment of Aged Acute Myeloid Leukemia
Objective To investigate the therapeutic effect of B-cell lymphoma-2(BCL-2)inhibitors in the treatment of senile acute myeloid leukemia,and to provide practical basis for the treatment of senile acute myeloid leukemia.Methods Thirty elderly patients with acute myeloid leukemia admitted to the Department of Oncology and Hematol-ogy in Jiugang Hospital of Gansu Province from January 2020 to October 2023 were selected as the study objects,and were divided into control group(15 cases)and intervention group(15 cases)according to random number table method.The intervention group was treated with BCL-2 inhibitor and the control group was treated with conventional treatment.The effect and incidence of adverse reactions were compared between the two groups.Results After treat-ment,the improvement rate of the intervention group(86.67%)was significantly higher than that of the control group(46.67%),and the difference was statistically significant(χ2=5.400,P<0.05).After treatment,the hematological index of the intervention group was significantly better than that of the control group,the difference was statistically signifi-cant(P<0.05).The immunological index of the intervention group was better than that of the control group,and the dif-ference was statistically significant(P<0.05).The total incidence of adverse reactions in the intervention group was sig-nificantly lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion In the treatment of elderly patients with acute myeloid leukemia,the combination of BCL-2 inhibitors can effectively im-prove the hematological and immunological indexes of patients,promote the improvement of the disease,and reduce the incidence of adverse reactions.
NETL
NSTL
万方数据
